Phase II Study of Arimoclomol in IBM FDA-OOPD

Authors

  • Mazen M. Dimachkie MD Department Neurology, University of Kansas Medical Center, Kansas City, KS USA 66061
  • Michael Hanna MD Institute of Neurology, University College of London, United Kingdom, London WC1E 6BT
  • Pedro Machado MD Institute of Neurology, University College of London, United Kingdom, London WC1E 6BT
  • Laura Herbelin BS Department Neurology, University of Kansas Medical Center, Kansas City, KS USA 66061
  • Mamatha Pasnoor MD Department Neurology, University of Kansas Medical Center, Kansas City, KS USA 66061
  • Omar Jawdat MD Department Neurology, University of Kansas Medical Center, Kansas City, KS USA 66061
  • April McVey MD Department Neurology, University of Kansas Medical Center, Kansas City, KS USA 66061
  • Jeffery Statland MD Department Neurology, University of Kansas Medical Center, Kansas City, KS USA 66061
  • Melanie D. Glenn MD Department Neurology, University of Kansas Medical Center, Kansas City, KS USA 66061
  • Linda Greensmith PhD Institute of Neurology, University College of London, United Kingdom, London WC1E 6BT
  • William Martens BA Department of Neurology, University of Rochester, Rochester, NY USA 14627
  • Rabi Tawil MD Department of Neurology, University of Rochester, Rochester, NY USA 14627
  • Michael McDermott PhD Department of Neurology, University of Rochester, Rochester, NY USA 14627
  • Richard J. Barohn MD Department Neurology, University of Kansas Medical Center, Kansas City, KS USA 66061

DOI:

https://doi.org/10.17161/rrnmf.v2i3.15728

Keywords:

Inclusion Body Myositis, Arimoclomol, Muscle Study Group

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.
2 images; one of a man in a backwards baseball cap on a cell phone, and a second image of a woman on a cell phone

Downloads

Published

2021-08-03

Issue

Vol. 2 No. 3 (2021)

Section

Proposed Stuff (Funded or unfunded grant proposals)

License

Copyright (c) 2021 Mazen Dimachkie MD, Michael Hanna MD, Pedro Machado MD, Laura Herbelin BS, Mamatha Pasnoor MD, Omar Jawdat MD, April McVey MD, Jeffery Statland MD, Melanie Glenn MD, Linda Greensmith PhD, Bill Martens PhD, Rabi Tawil MD, Michael McDermott PhD, Richard Barohn MD

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

How to Cite

Dimachkie , M. M., Hanna , M., Machado, P. ., Herbelin, L. ., Pasnoor, M. ., Jawdat, O., McVey , A. ., Statland, J. ., Glenn, M. D., Greensmith , L. ., Martens , B. ., Tawil, R. ., McDermott, M. ., & Barohn, R. J. (2021). Phase II Study of Arimoclomol in IBM FDA-OOPD . RRNMF Neuromuscular Journal, 2(3), 104-142. https://doi.org/10.17161/rrnmf.v2i3.15728